CompletedPhase 3NCT00672022
Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses
Studying Gangliosidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's National Research Institute
- Principal Investigator
- Cynthia J TIfft, MD, PhD, M.DChildren's National Research Institute
- Intervention
- Zavesca (Miglustat)(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2004 – 2007
Study locations (1)
- Children's National Medical Center, Washington D.C., District of Columbia, United States
Collaborators
Actelion
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00672022 on ClinicalTrials.govOther trials for Gangliosidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07082543A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisAzafaros A.G.
- RECRUITINGPHASE1, PHASE2NCT03952637A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT00668187A Natural History Study of the GangliosidosesUniversity of Minnesota